Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 7/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.64 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 11/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 9/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229135 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL13897130 | 0.87 | SLC1A2 (0.62) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL5325249 | 0.85 | SLC1A2 (0.53) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| Hydrochloric Acid SCHEMBL27842023 | 0.85 | SLC1A2 (0.60) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL25660588 | 0.83 | SLC1A2 (0.65) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL24520312 | 0.82 | SLC1A1 (0.52) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL5322811 | 0.82 | ALOX15 (0.59) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL3514787 | 0.80 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL3514785 | 0.80 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL5279387 | 0.79 | SLC1A1 (0.65) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-10738083-B2 | Influenza virus neutralizing peptidomimetic compounds | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2020-08-11 | — | — | US | claimed |
| US-20180118788-A1 | INFLUENZA VIRUS NEUTRALIZING PEPTIDOMIMETIC COMPOUNDS | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2018-05-03 | — | — | US | claimed |
| EP-3294753-A1 | INFLUENZA VIRUS NEUTRALIZING PEPTIDOMIMETIC COMPOUNDS | Janssen Vaccines & Prevention B.V. (NL) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180826-A1 | INFLUENZA VIRUS NEUTRALIZING PEPTIDOMIMETIC COMPOUNDS | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2016-11-17 | — | — | WO | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| WO-2024043250-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20180118788-A1 | INFLUENZA VIRUS NEUTRALIZING PEPTIDOMIMETIC COMPOUNDS | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2018-05-03 | — | — | US | disclosed |
| EP-3294753-A1 | INFLUENZA VIRUS NEUTRALIZING PEPTIDOMIMETIC COMPOUNDS | Janssen Vaccines & Prevention B.V. (NL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2016180826-A1 | INFLUENZA VIRUS NEUTRALIZING PEPTIDOMIMETIC COMPOUNDS | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2016-11-17 | — | — | WO | disclosed |
| EP-2352746-A1 | BIOACTIVE COMPOUNDS | Universiti Teknologi Mara (MY) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010062159-A1 | BIOACTIVE COMPOUNDS | UNIVERSITI TEKNOLOGI MARA (MY) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738083-B2 | Influenza virus neutralizing peptidomimetic compounds | ANPEP, NEU1, NGLY1 | SLC1A2 3932/4885SLC1A1 2249/4885SLC1A3 1971/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | SLC1A2 4743/4885SLC1A1 4584/4885SLC1A3 4360/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC1A2 138/4885SLC1A1 289/4885SLC1A3 219/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | SLC1A2 1665/4885SLC1A1 1666/4885SLC1A3 1372/4885 |
| US-20180118788-A1 | INFLUENZA VIRUS NEUTRALIZING PEPTIDOMIMETIC COMPOUNDS | ANPEP, NEU1, NGLY1 | SLC1A2 3932/4885SLC1A1 2249/4885SLC1A3 1971/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | SLC1A2 146/4885SLC1A1 121/4885SLC1A3 74/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | SLC1A2 4743/4885SLC1A1 4584/4885SLC1A3 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.